Flushing, New York Clinical Trials

A listing of Flushing, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 508 clinical trials
Study Title Past Referrals2  

Study Overview

Site 3 Widget
 (8.8 away)
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

cytotoxic chemotherapy
hepatitis
renal function test
chemoimmunotherapy
hepatitis b surface antigen
Memorial Sloan-Kettering Cancer Cente
 (6.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

malt
alkylating agents
cyclophosphamide
systemic therapy
leukapheresis
Memorial Sloan Kettering Cancer Center
 (6.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +35 other locations
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

measurable disease
cancer
solid tumour
maintenance therapy
small cell lung cancer
Mount Sinai - PRIME; Icahn School of Medicine at Mount Sinai
 (5.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +146 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

hypertension
HIV Infection
connective tissue disease
macitentan 10 mg
left ventricular end-diastolic pressure
Mount Sinai
 (5.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +210 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

fatigue
solid tumour
prednisone
soft tissue lesion
adenocarcinoma of prostate
Research Site
 (4.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +106 other locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

Investigational Site Number 8400069
 (6.9 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +46 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

advanced breast cancer
er-positive breast cancer
oestrogen receptor positive breast cancer
locally advanced breast cancer
targeted therapy
Investigational Site Number 8400009
 (5.0 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +125 other locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease  

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

parkinsonism
bradykinesia
early parkinson's
tremor
dopamine
Neuroscience Institute at Great Neck
 (5.5 away)
  • 0 views
  • 28 Jun, 2022
  • +125 other locations
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

Mount Sinai Medical Center
 (5.9 away) Contact site
  • 0 views
  • 05 Oct, 2021
  • +301 other locations